Activation of MMPs by EZH2 Table S2 List of genes differentially expressed in PC3 cells after EZH2 knockdown using a Human Tumor Metastasis Real-time PCR Array. (DOC) Author Contributions Conceived and designed the experiments: YJS J-HK. Performed the experiments: YJS. Analyzed the data: YJS J-HK. Contributed reagents/ materials/analysis tools: J-HK. Wrote the paper: YJS J-HK. Table S3 (DOC) References Primers for RT-PCR and ChIP analyses. 1. Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nature reviews Cancer 2: 563–572. 2. Jarvelainen H, Sainio A, Koulu M, Wight TN, Penttinen R (2009) Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacological reviews 61: 198–223. 3. Deryugina EI, Quigley JP (2006) Matrix metalloproteinases and tumor metastasis. Cancer metastasis reviews 25: 9–34. 4. Friedl P, Wolf K (2003) Tumour-cell invasion and migration: diversity and escape mechanisms. Nature reviews Cancer 3: 362–374. 5. Freije JM, Balbin M, Pendas AM, Sanchez LM, Puente XS, et al. (2003) Matrix metalloproteinases and tumor progression. Adv Exp Med Biol 532: 91–107. 6. John A, Tuszynski G (2001) The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 7: 14–23. 7. Westermarck J, Kahari VM (1999) Regulation of matrix metalloproteinase expression in tumor invasion. Faseb J 13: 781–792. 8. Page-McCaw A, Ewald AJ, Werb Z (2007) Matrix metalloproteinases and the regulation of tissue remodelling. Nature reviews Molecular cell biology 8: 221–233. 9. Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circulation research 92: 827–839. 10. Gross J, Lapiere CM (1962) Collagenolytic activity in amphibian tissues: a tissue culture assay. Proceedings of the National Academy of Sciences of the United States of America 48: 1014–1022. 11. Bode W, Fernandez-Catalan C, Grams F, Gomis-Ruth FX, Nagase H, et al. (1999) Insights into MMP-TIMP interactions. Ann N Y Acad Sci 878: 73–91. 12. Brew K, Nagase H (2010) The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochimica et biophysica acta 1803: 55–71. 13. Pulukuri SM, Patibandla S, Patel J, Estes N, Rao JS (2007) Epigenetic inactivation of the tissue inhibitor of metalloproteinase-2 (TIMP-2) gene in human prostate tumors. Oncogene 26: 5229–5237. 14. Brehmer B, Biesterfeld S, Jakse G (2003) Expression of matrix metalloprotei- nases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue. Prostate cancer and prostatic diseases 6: 217–222. 15. Khokha R, Waterhouse P, Yagel S, Lala PK, Overall CM, et al. (1989) Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. Science 243: 947–950. 16. Denhardt DT, Khokha R, Yagel S, Overall CM, Parhar RS (1992) Oncogenic consequences of down-modulating TIMP expression in 3T3 cells with antisense RNA. Matrix 1: 281–285. 17. Imren S, Kohn DB, Shimada H, Blavier L, DeClerck YA (1996) Overexpression of tissue inhibitor of metalloproteinases-2 retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion. Cancer research 56: 2891–2895. 18. Watanabe M, Takahashi Y, Ohta T, Mai M, Sasaki T, et al. (1996) Inhibition of metastasis in human gastric cancer cells transfected with tissue inhibitor of metalloproteinase 1 gene in nude mice. Cancer 77: 1676–1680. 19. Khokha R, Zimmer MJ, Graham CH, Lala PK, Waterhouse P (1992) Suppression of invasion by inducible expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in B16-F10 melanoma cells. Journal of the National Cancer Institute 84: 1017–1022. 20. Leco KJ, Khokha R, Pavloff N, Hawkes SP, Edwards DR (1994) Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. The Journal of biological chemistry 269: 9352–9360. 21. DeClerck YA, Perez N, Shimada H, Boone TC, Langley KE, et al. (1992) Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer research 52: 701–708. 22. Wang M, Liu YE, Greene J, Sheng S, Fuchs A, et al. (1997) Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. Oncogene 14: 2767–2774. 23. Kawamata H, Kawai K, Kameyama S, Johnson MD, Stetler-Stevenson WG, et al. (1995) Over-expression of tissue inhibitor of matrix metalloproteinases (TIMP1 and TIMP2) suppresses extravasation of pulmonary metastasis of a rat bladder carcinoma. International journal of cancer Journal international du cancer 63: 680–687. 24. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, et al. (2002) Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298: 1039–1043. 25. Kirmizis A, Bartley SM, Kuzmichev A, Margueron R, Reinberg D, et al. (2004) Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev 18: 1592–1605. 26. Simon JA, Lange CA (2008) Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutation research 647: 21–29. 27. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, et al. (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624–629. 28. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, et al. (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 100: 11606–11611. 29. Weikert S, Christoph F, Kollermann J, Muller M, Schrader M, et al. (2005) Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med 16: 349–353. 30. Sudo T, Utsunomiya T, Mimori K, Nagahara H, Ogawa K, et al. (2005) Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer 92: 1754–1758. 31. Beke L, Nuytten M, Van Eynde A, Beullens M, Bollen M (2007) The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2. Oncogene 26: 4590–4595. 32. Karanikolas BD, Figueiredo ML, Wu L (2009) Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line. Molecular cancer research : MCR 7: 1456–1465. 33. Chen S, Bohrer LR, Rai AN, Pan Y, Gan L, et al. (2010) Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nature cell biology 12: 1108–1114. 34. Chen H, Tu SW, Hsieh JT (2005) Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. The Journal of biological chemistry 280: 22437–22444. 35. Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, et al. (2010) An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nature medicine 16: 286–294. 36. Yu J, Cao Q, Mehra R, Laxman B, Yu J, et al. (2007) Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell 12: 419–431. 37. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, et al. (2006) The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439: 871–874. 38. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, et al. (2008) Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 27: 7274–7284. 39. Yu J, Cao Q, Yu J, Wu L, Dallol A, et al. (2010) The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer. Oncogene 29: 5370–5380. 40. Rao ZY, Cai MY, Yang GF, He LR, Mai SJ, et al. (2010) EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients. Carcinogenesis 31: 1576–1583. 41. Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, et al. (2008) Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 40: 741–750. 42. Trojan L, Schaaf A, Steidler A, Haak M, Thalmann G, et al. (2005) Identification of metastasis-associated genes in prostate cancer by genetic profiling of human prostate cancer cell lines. Anticancer research 25: 183–191. 43. Albrecht AL, Singh RK, Somji S, Sens MA, Sens DA, et al. (2008) Basal and metal-induced expression of metallothionein isoform 1 and 2 genes in the RWPE-1 human prostate epithelial cell line. J Appl Toxicol 28: 283–293. 44. Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D (2002) Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev 16: 2893–2905. 45. Srinivasan L, Atchison ML (2004) YY1 DNA binding and PcG recruitment requires CtBP. Genes & development 18: 2596–2601. 46. Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, et al. (2003) A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nature medicine 9: 407–415. 47. Bian J, Wang Y, Smith MR, Kim H, Jacobs C, et al. (1996) Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3. Carcinogenesis 17: 1805–1811. 48. Anania MC, Sensi M, Radaelli E, Miranda C, Vizioli MG, et al. (2011) TIMP3 regulates migration, invasion and in vivo tumorigenicity of thyroid tumor cells. Oncogene 30: 3011–3023. 49. Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, et al. (2003) A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of PLoS ONE | www.plosone.org 11 January 2012 | Volume 7 | Issue 1 | e30393